ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone207-878-2770
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.99 million
Profitability
Miscellaneous
Employees47
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
ImmuCell (NASDAQ:ICCC) Frequently Asked Questions
What is ImmuCell's stock symbol?
ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."
How were ImmuCell's earnings last quarter?
ImmuCell Co. (NASDAQ:ICCC) released its earnings results on Monday, August, 12th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter. The biotechnology company earned $2.71 million during the quarter. ImmuCell had a negative net margin of 14.61% and a negative return on equity of 6.84%. View ImmuCell's Earnings History.
When is ImmuCell's next earnings date?
Has ImmuCell been receiving favorable news coverage?
Media headlines about ICCC stock have trended negative on Thursday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ImmuCell earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for ImmuCell.
Are investors shorting ImmuCell?
ImmuCell saw a increase in short interest in August. As of August 15th, there was short interest totalling 2,000 shares, an increase of 33.3% from the July 15th total of 1,500 shares. Based on an average daily trading volume, of 6,800 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the company's shares are short sold. View ImmuCell's Current Options Chain.
Who are some of ImmuCell's key competitors?
Some companies that are related to ImmuCell include Nymox Pharmaceutical (NYMX), Vermillion (VRML), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Arca Biopharma (ABIO), Akers Biosciences (AKER), BG Medicine (BGMD), Fluoropharma Medical (FPMI) and Response Genetics (RGDXQ).
What other stocks do shareholders of ImmuCell own?
Who are ImmuCell's key executives?
ImmuCell's management team includes the folowing people:
- Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
- Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
- Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
- Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)
Who are ImmuCell's major shareholders?
ImmuCell's stock is owned by many different of retail and institutional investors. Top institutional investors include Perritt Capital Management Inc. (1.80%), Ingalls & Snyder LLC (1.33%), Vanguard Group Inc. (1.30%), HM Payson & Co. (0.40%) and Eidelman Virant Capital (0.19%). View Institutional Ownership Trends for ImmuCell.
Which institutional investors are selling ImmuCell stock?
Which institutional investors are buying ImmuCell stock?
How do I buy shares of ImmuCell?
Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ImmuCell's stock price today?
One share of ICCC stock can currently be purchased for approximately $5.46.
How big of a company is ImmuCell?
What is ImmuCell's official website?
How can I contact ImmuCell?
ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]
MarketBeat Community Rating for ImmuCell (NASDAQ ICCC)
MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe ICCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
